Artwork

Content provided by Oncolgy Times and Audio Medica. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Oncolgy Times and Audio Medica or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

"Promising Activity" Of Cetuximab In Patients With Advanced Biliary Cancer

2:18
 
Share
 

Manage episode 153458751 series 1090654
Content provided by Oncolgy Times and Audio Medica. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Oncolgy Times and Audio Medica or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
BARCELONA, SPAIN—Adding cetuximab to gemcitabine/oxaliplatin (GEMOX) chemotherapy controlled disease among two thirds of patients with advanced biliary cancer in a trial reported at the World Congress on Gastrointestinal Cancer. Éveline Boucher from the Centre Eugene Marquis, in Rennes, France, presented preliminary findings from a phase II open-label study among 101 patients who had not already received palliative treatment for their advanced biliary cancers, and had WHO performance status 0-1. She discussed her team’s findings with Peter Goodwin.
  continue reading

19 episodes

Artwork
iconShare
 
Manage episode 153458751 series 1090654
Content provided by Oncolgy Times and Audio Medica. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Oncolgy Times and Audio Medica or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
BARCELONA, SPAIN—Adding cetuximab to gemcitabine/oxaliplatin (GEMOX) chemotherapy controlled disease among two thirds of patients with advanced biliary cancer in a trial reported at the World Congress on Gastrointestinal Cancer. Éveline Boucher from the Centre Eugene Marquis, in Rennes, France, presented preliminary findings from a phase II open-label study among 101 patients who had not already received palliative treatment for their advanced biliary cancers, and had WHO performance status 0-1. She discussed her team’s findings with Peter Goodwin.
  continue reading

19 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide